DAFTAR PUSTAKA

Apple F.S. 2007. Basics of cardiac troponin: Practical aspects of assays, potential analytical
confounders, and clinical interpretation. In: Adams J.E., Apple F.S., Jaffe A. Markers in
Cardiology. Massachusetts: Blackwell Publishing, pp: 3-14.
Anderson J.L., Adams C.D., Antman E.M., Bridges C.R., Califf R.M., Casey D.E., Chavey W.E.
2007. ACC/AHA 2007 guidelines for the management of patients with unstable angina/nonSTelevation myocardial infarction. Circulation. 116: 148-164.
Anonim. 2010. Vidas troponin I assay. Biomerieux.
Anonim. 2011. Presage ST2 Assay - Instructions for Use. Critical Diagnostics
Anonim. 2012. Presage ST2 Assay EIA Test Kit. Critical Diagnostics
Anonim. 2015. Aspect-Plus ST2 Rapid Test. Critical Diagnostics
Antman E.M., Tanasijevic M.J., Thompson B., Schactmen M., McCabe C.H., Cannon C.P., Fischer
G.A. 2006. Cardiac-specific troponin-I levels to predict the risk of mortality in patients with
acute coronary syndromes. NEJM. 335 (18): 1333-1339.
Ardhana T., Aminuddin M., Nugraha J. 2013. Relationship between NT-proBNP level and protein
ST2 level. Folia Med Ind. 49 (4): 202-207.
Bhardwaj A. & Januzzi J.L. 2010. ST2: A novel biomarker for heart failure. Expert Rev Mol
Diagn.10: 459464.
Bhatt D.L. & Flather M.D. 2004. Handbook of Acute Coronary Syndromes. London: Remedica
Publishing, pp: 1-26.
Body R., McDowell G., Carley S., Ferguson J., Mackway-Jones K. 2010. Diagnosing acute
myocardial infarction with troponins: How low can you go? Emerg Med J. 27: 292-296.
Boyle A.J. & Jaffe A.S. 2009. Acute myocardial infarction. In: Crawford M.H. Current Diagnosis &
Treatment: Cardiology. 3rd Ed. San Fransisco: The McGraw-Hill Companies Inc, pp: 51-72.
Brown A.M., Wu A.H., Clopton P., Robey J.L., Hollander J.E. 2007. Soluble ST2 in emergency
department chest pain patients with potential acute coronary syndromes. Ann Emerg Med. 50:
153158.
Caselli C. 2014. Inflammation in cardiac disease: focus on interleukin-33/ST2 pathway. Inflamm Cell
Signal. 1: 146-149.
Chen L.Q., Lemos J.A., Das S.R., Ayers C.R., Rohatgi A. 2013. Soluble ST2 is associated with allcause and cardiovascular mortality in a population-based cohort: The Dallas Heart Study. Clin
Chem. 59: 536546.
Chew D.P. & White H.D. 2004. Pathophysiology, Classification, and Clinical Ceatures. In: Bhatt D.L.
& Flather M.D. Handbook of Acute Coronary Syndromes. London: Remedica Publishing, pp: 120.
Chien I.T., Kao J.T., Lin P.C., Lai H.H., Hsu C.A., Chuang Y.K. Chien M.J. et al. 2010. Comparison
of the analytical performance for measurement of cardiac troponin I. J Biomed Lab Sci. 22 (3):
110-115.
Ciccone M.M., Cortese F., Gesualdo M., Riccardi R., Nunzio D.D., Moncelli M., Iacoviello M., et al.
2013. Novel cardiac bio-marker: ST2. A review. Molecules. 18: 15314-15328.
Cohen R.E., Kukar A., Frankenberger O., Greenberg H.H. 2008. Coronary artery spasm and chest
pain with normal coronary arteries. In: Hong M.K. & Herzog E. Acute Coronary Syndrome
Multidisciplinary and Pathway-Based Approach. 9th Ed. London: Spinger-Verlag London
Limited, pp: 246-254.
Dahlan M.S. 2011. Penelitian Prognostik dan Sistem Skoring: disertai praktik dengan SPSS dan
STATA. Bandung: Alqaprint Jatinangor, pp: 37-46.
Daniels L.B., Clopton P., Iqbal N., Tran K., Maisel A.S. 2010. Association of ST2 levels with cardiac
structure and function and mortality in outpatients. Am Heart J. 160: 721728.
Daubert M.D. & Jeremias A. 2010. The utility of troponin measurement to detect myocardial
infarction: review of the current findings. Vasc Health Risk Manag. 6: 691699.

Dhillon O.S., Narayan H.K., Quinn P.A., Squire I.B., Davies J.E., Ng L.L. 2011. Interleukin 33 and
ST2 in non-ST-elevation myocardial infarction: Comparison with global registry of acute
coronary events risk scoring and NT-proBNP. Am Heart J. 161: 11631170.
Diez J. 2008. Serum soluble ST2 as a biochemical marker of acute heart failure. J Am Coll Cardiol.
52: 14661467.
Ditjen Yanmed. 2005. Statistik Rumah Sakit di Indonesia. Morbiditas dan Mortalitas. Seri 3. Jakarta:
Departemen Kesehatan Republik Indonesia, pp: 34-45.
Dzankovic A.M. & Pojskic B. 2007. Acute heart failure after myocardial infarction. BJBMS. 7: 40-47.
Eftekhari H., Bukharovich I., Aziz E., Hong M.K. 2008. Epidemiology and pathophysiology of acute
coronary syndrome. In: Hong M.K. & Herzog E. Acute Coronary Syndrome Multidisciplinary
and Pathway-Based Approach. 9th Ed. London: Spinger-Verlag London Limited, pp: 246-254.
Eggers K.M., Armstrong P.W., Califf R.M., Simons M.L., Venge P., Wallentin L., James S.K. 2010.
ST2 and mortality in non ST-segment elevation acute coronary syndrome. Am Heart J. 159:
788794.
El-Menyar A., Zubaid M., Al Mahmeed W., Sulaiman K., Alnabti A., Singh R., Al-Suwaidi J. 2012.
Killip classification in patients with acute coronary syndrome: insight from a multicenter
registry. Am J Emerg Med. 30: 97-103.
Gorman L.S. 2007. Assessment of cardiovascular disorders, capter 7. In: Arneson W. & Brickell J.
Clinical Chemistry A Laboratory Perspective. Philadelphia: F.A. Davis Company, pp: 270-275.
Granger C.B. 2004. Epidemiology. In: Bhatt D.L. & Flather M.D. Handbook of Acute Coronary
Syndromes. London: Remedica Publishing, pp: 23-36.
Gray H.H., Dawkins K.D., Morgan J.M., Simpson I.A. 2005. Lecture Notes Cardiology. Edisi ke 4.
Surabaya: Erlangga Medical Series, pp: 80-87.
Hallen J. 2012. Troponin for the estimation of infarct size: What have we learned? Cardiology. 121:
204-212.
Januzzi J.L., Camargo C.A., Anwaruddin S., Baggish A.L., Chen A.A., Krauser D.G., Simons M.A.,
et al. 2005. The N-terminal pro-BNP investigation of dyspnea in the emergency department
(PRIDE) study. Am J Cardiol. 95 (8): 948954.
Kakkar R. & Lee R.T. 2008. The IL-33/ST2 pathway: therapeutic target and novel biomarker. NRDD.
7: 827840.
Kalyanasundaram
A.
&
Shirani
J.
2009.
Acute
Coronary
Syndrome.
http://emedicine.medscape,com/article/1910735 (diunduh 14 Juni 2015).
Karo-karo S., Rahajoe A.U., Sulistyo S., Kosasih A. 2012. Buku Panduan Kursus Bantuan Hidup
Jantung Lanjut Indonesia. Edisi 2012. Jakarta: Perhimpunan Dokter Spesialis Kardiovaskuler
Indonesia (PERKI), pp: 60-76.
Kimmenade R.R. & Januzzi J.L. 2012. Emerging biomarkers in heart failure. Clin Chem. 58: 127
138.
Klabunde R.E. 2005. Celluler structure and function. In: Klabunde R.E. (Ed). Cardiovascular
Physiology Concepts. Philadelphia: Lippincot Williams and Wilkins, pp: 41-57.
Kohli P., Bonaca M.P., Kakkar R., Kudinova A.Y., Scirica B.M., Sabatine M.S., Murphy S.A., et al.
2012. Role of ST2 in non ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial.
Clin Chem. 58: 257266.
Linnet K. & Boyd J.C. 2006. Selection and analytical evaluation of methods-with statistical
techniques. In: Burtis C.A., Ashwood E.A., Bruns D.E. Tiets Textbook of Clinical Chemistry
and Molecular Diagnostic. 4th Ed. Missouri: Elsevier Saunders, pp: 353-407.
Madiyono B., Moeslichan M., Sastroasmoro S., Budiman I., Purwanto S.H. 2008. Perkiraan besar
sampel. In: Sastroasmoro S. & Ismail S. Dasar-dasar Metodologi Penelitian Klinis. Jakarta:
Sagung Seto, pp: 302-331.
Mann D.L., Zipes D.P., Libby P., Bonow R.O. 2015. Braunwalds Heart Disease A Textbook of
Cardiovascular Medicine. 10th Ed. Boston: Elsevier, pp: 1033-1089.
Manzano-Fernandez S., Mueller T., Pascual-Figal D., Truong Q.A., Januzzi J.L. 2011. Usefulness of
soluble concentrations of interleukin family member ST2 as predictor of mortality in patients
with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J
Cardiol.107: 259267.

Mehta P.K. & Griendling K.K. 2007. Angiotensin II cell signaling: physiological and pathological
effects in the cardiovascular system. Am J Physiol Cell Physiol. 292: 8297.
Melanson S.E.F., Tanasijevic M.J., Jarolim P. 2007. Cardiac troponin assays. A view from the clinical
chemistry laboratory. Circulation. 116: 501-504.
Mendis S., Thygesen K., Kuulasmaa K., Giampaoli S., Mahonen M., Blackett K.N., Lisheng L., et al.
2010. World Health Organization definition of myocardial infarction: 2008-2009 revision. Int J
Epidemiol. 40: 139-146.
Morrow D.A. 2006. Cardiovascular Biomarkers: Pathophysiology and Disease Management. Boston:
Humana Press Inc, pp: 28-35.
Mozaffarian D., Banjamin E.J., Go A.S., Arnett D.K., Blaha M.J., Cushman M., Ferranti S. , et al.
2015. Heart disease and stroke statistics 2015 update. AHA Inc. Circulation. 131: 154-156.
Mueller T. & Jaffe A.S. 2015. Soluble ST2 analytical considerations. Am J Cardiol. 115 (7): 1-6.
Odelson J.E. 2011. Heart failure with preserved ejection fraction. AHA. Circulation. 124: 540-543.
Ohman E.M., Armsrtong P.W., Chistenson R.H., Granger C.B., Katus H.A., Hamm C.W., OHanesian
M.A., et al. 2006. Cardiac troponin-T levels for risk stratification in acute myocardial ischemia.
GUSTO IIA Investigators. NEJM. 335 (18): 1333-1341.
Pascual-Figal D.A., Manzano-Fernandez S., Boronat M., Casas T., Garrido I.P., Bonaque J.C., PastorPerez F., et al. 2011. Soluble ST2, high-sensitivity troponin T and N-terminal pro-B-type
natriuretic peptide: Complementary role for risk stratification in acutely decompensated heart
failure. Eur J Heart Fail. 13: 718725.
Pascual-Figal D.A., Januzzi J.L. 2015. The biology of ST2: The international ST2 consensus panel.
Elsevier. Am J Cardiol. 115 (7): 1-6.
Perhimpunan Dokter Spesialis Kardiovaskuler Indonesia (PERKI). 2015. Pedoman Tatalaksana
Sindrom Koroner Akut. Edisi ke 3, pp: 1-9.
Priyanto H., Nugraha J., Edijanto S.P. 2014. Suppression of tumorigenicity-2 di Infark miokard akut.
Ind J Clin Pat Med Lab. 20: 176-179.
Rehman S.U., Mueller T., Januzzi J.L.Jr. 2008. Characteristics of the novel interleukin family
biomarker ST2 in patients with acute HF. J Am Coll Cardiol. 52: 14581465
Riskesdas. 2013. Badan Penelitian dan Pengembangan Kesehatan Departemen Kesehatan Republik
Indonesia. Laporan Nasional Riset Kesehatan Dasar (Riskesdas) 2013. Jakarta: Departemen
Kesehatan Republik Indonesia, pp: 43-53.
Rosenkranz S. 2004. TGF-h1 and angiotensin networking in cardiac remodeling. Elsevier. J
Cardiores. 63: 423 432.
Sabatine M.S., Morrow D.A., Higgins L.J., MacGillivray C., Guo W., Bode C., Rifai N., et al. 2008.
Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone
B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 117:
19361944.
Sanada S., Hakuno D., Higgins L.J., Schreiter E.R., McKenzie A.N., Lee R.T. 2007. IL-33 and ST2
comprise a critical biomechanically induced and cardioprotective signaling system. J Clin
Invest. 117: 15381549.
Sarko J. 2002. Cardiac troponin. J Em Med. 23 (1): 5765.
Sastroasmoro S. & Ismael S. 2008. Dasar-dasar Metodologi Penelitian Klinis. Edisi ke 3. Jakarta:
Sagung Seto, pp: 147-164.
Sayehmiri K., Sarokhani D., Jahanihashemi H., Sayehmiri A., Sarokhani M.T., Hemati F., Bakhshi E.,
et al. 2012. Prediction of survival after myocardial infarction using Killip class. Int J Clin Med.
3: 563-567.
Shah R.V., Januzzi J.L. 2010. ST2: A novel remodeling biomarker in acute and chronic heart failure.
Curr Heart Fail Rep. 7: 914.
Sharma S., Jackson P.G., Makan J. 2004. Cardiac troponins. J Clin Pathol. 57: 1025-1026.
SIGN (Scottish Intercollegiate Guidelines Network). 2007. Acute Coronary Syndromes: a national
clinical guideline. http://www.sign.ac.uk/pdf/sign93.pdf (diunduh 12 Juni 2015).
Thygesen K., Alpert J.S., Jaffe A.S., Simoons M.L., Chaitman B.R., White H.D., Katus H.A., et al.
2012. Third universal definition of myocardial infarction. J Am Coll Cardiol. 60: 15811598.
Thygesen K., Alpert S.J., White H.D. 2007. Universal definition of myocardial infarction. Circulation.
116: 26342653.

Veronique R.L. 2007. Epidemiology of myocardial infarction. Med Clin North Am. 914: 536-537.
Viereck J., Bang C., Foinquinos A., Thum T. 2014. Regulatory RNAs and paracrine networks in the
heart. European Society of Cardiology. J Cardiores. 102: 290301.
Weinberg E.O. 2009. Suppression of tumorigenicity 2 protein in heart disease: From discovery to
mechanisms and prognostic value. Biomark Med. 3: 495511.
Weir R.A., Miller A.M., Murphy G.E., Clements S., Steedman T., Connell J.M., McInnes I.B., et al.
2010. Serum soluble ST2: A potential novel mediator in left ventricular and infarct remodeling
after acute myocardial infarction. J Am Coll Cardiol. 55: 243250.
White H.D. 2011. Pathobiology of troponin elevations. Do elevations occur with myocardial ischemia
as well as necrosis? JACC. 57 (24): 24062408.
Wijono W., Wiadnyana I.G.P., Nendroduwito D., Yamin G., Trisnawati., Yusnayanti. 2004.
Pedoman Praktek Laboratorium yang Benar (Good Laboratory Practice). Cetakan ke-3.
Jakarta: Dirjen LabKes, Dirjen Yanmed, Departemen Kesehatan RI, pp: 55-62.
Xanthakis V., Larson M.G., Wollert K.C., Aragam J., Cheng S., Ho J., Coglianese E., et al. 2013.
Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and
dysfunction. J Am Heart Assoc. 2: 397-399.